Search results for "circulating"

showing 10 items of 173 documents

P1.13-16 The Diagnostic Accuracy of Circulating Tumor DNA for the Detection of EGFR-T790M Mutation in NSCLC: A Systematic Review and Meta-Analysis

2018

0301 basic medicinePulmonary and Respiratory Medicinebusiness.industryDiagnostic accuracyEGFR T790M03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyCirculating tumor DNA030220 oncology & carcinogenesisMeta-analysisMutation (genetic algorithm)Cancer researchMedicinebusinessJournal of Thoracic Oncology
researchProduct

Technical Aspects for the Evaluation of Circulating Nucleic Acids (CNAs): Circulating Tumor DNA (ctDNA) and Circulating MicroRNAs

2017

Circulating nucleic acids (CNAs), for example, circulating tumor DNA (ctDNA) and circulating microRNA (miRNA), represent promising biomarkers in several diseases including cancer. They can be isolated from many body fluids, such as blood, saliva, and urine. Also ascites, cerebrospinal fluids, and pleural effusion may be considered as a source of CNAs, but with several and intrinsic limitations. Therefore, blood withdrawal represents one of the best sources for CNAs due to the very simple and minimally invasive way of sampling. Moreover, it can be repeated at different time points, giving the opportunity for a real-time monitoring of the disease.

0301 basic medicineSalivabusiness.industryCancerDiseaseCirculating Nucleic Acids CNAs Circulating Tumor DNA ctDNA Circulating MicroRNAs microRNAsmedicine.diseaseMany body03 medical and health sciencesCirculating MicroRNA030104 developmental biology0302 clinical medicineCirculating tumor DNA030220 oncology & carcinogenesismicroRNACancer researchmedicineNucleic acidbusiness
researchProduct

Diagnostic and Prognostic Relevance of Red Blood Cell Distribution Width for Vascular Aging and Cardiovascular Diseases.

2019

Evidence suggests association of red blood cell distribution width (RDW) with cardiovascular diseases (CVDs). On the contrary, we underline that the sole RDW values cannot represent a valid CVD biomarker. High RDW values are expression of biological effects of a lot of both endogenous and exogenous factors (i.e., age, sex, genetic background, inflammation, hormones, drugs, diet, exercise, hematological analyzers, and ranges of values), modulating the biology and physiology of erythrocytes. Thus, the singular monitoring of RDW cannot be used to predict cardiovascular disorders. Accordingly, we have reviewed the evidence for potential relationship of RDW values with alterations in the cardiov…

0301 basic medicineSenescenceErythrocyte Indicescirculating endothelial progenitor cells and nucleated red blood cellAgingleukocyte telomere lengthsInflammationDiseaseBioinformaticsEpigenesis Geneticleukocyte telomere length03 medical and health sciencesCVDs; RDW; circulating endothelial progenitor cells and nucleated red blood cells; leukocyte telomere lengths; vascular aging; Aging; Biomarkers; Cardiovascular Diseases; Epigenesis Genetic; Humans; Prognosis; Erythrocyte Indices0302 clinical medicineGeneticmedicineRDW; CVDs; vascular ageing; leukocyte telomere lengths; circulating endothelial progenitor cells and nucleated red blood cells.Settore MED/05 - Patologia ClinicaRDWHumansCVDsProgenitor cellvascular ageingbusiness.industryNucleated Red Blood CellRed blood cell distribution widthCVDPrognosisSettore MED/23030104 developmental biologyvascular agingCardiovascular DiseasesBiomarker (medicine)Geriatrics and Gerontologymedicine.symptombusiness030217 neurology & neurosurgerycirculating endothelial progenitor cells and nucleated red blood cellsBiomarkersHormoneEpigenesisRejuvenation research
researchProduct

Evaluation of the Possibility to Detect Circulating Tumor DNA From Pituitary Adenoma

2019

Objective: Circulating free DNA (cfDNA) in general and circulating tumor DNA (ctDNA) in particular is becoming an increasingly used form of liquid biopsy biomarkers. In this study, we are investigating the ability to detect ctDNA from the plasma of pituitary adenoma (PA) patients. Design: Tumor tissue samples were obtained from planed PA resections, before which blood plasma samples were taken. Somatic variants found in PA tissue samples were evaluated in related cfDNA, isolated from plasma samples. Methods: Sanger sequencing, as well as previously obtained whole-exome sequencing data, were used to evaluate somatic variants composition in tumor tissue samples. cfDNA was isolated from the sa…

0301 basic medicineSomatic cellEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismpituitary adenomaBiologylcsh:Diseases of the endocrine glands. Clinical endocrinologyDNA sequencing03 medical and health sciencessymbols.namesakeGNAS0302 clinical medicineEndocrinologyBlood plasmaTaqManGNAS complex locusLiquid biopsyOriginal ResearchSanger sequencingcirculating tumor DNAlcsh:RC648-665AmpliconMolecular biology030104 developmental biologybiology.proteinsymbolsnext-generation sequencingcompetitive allele-specific TaqManFrontiers in Endocrinology
researchProduct

Small RNA-seq analysis of circulating miRNAs to identify phenotypic variability in Friedreich's ataxia patients.

2018

AbstractFriedreich’s ataxia (FRDA; OMIM 229300), an autosomal recessive neurodegenerative mitochondrial disease, is the most prevalent hereditary ataxia. In addition, FRDA patients have shown additional non-neurological features such as scoliosis, diabetes, and cardiac complications. Hypertrophic cardiomyopathy, which is found in two thirds of patients at the time of diagnosis, is the primary cause of death in these patients. Here, we used small RNA-seq of microRNAs (miRNAs) purified from plasma samples of FRDA patients and controls. Furthermore, we present the rationale, experimental methodology, and analytical procedures for dataset analysis. This dataset will facilitate the identificatio…

0301 basic medicineStatistics and ProbabilityEpigenomicsSmall RNAData DescriptorAtaxiaMitochondrial diseaseLibrary and Information SciencesBioinformaticsEducation03 medical and health sciences0302 clinical medicinemicroRNAMedicineHumansCirculating MicroRNAPathologicalCause of deathbusiness.industrySequence Analysis RNAHypertrophic cardiomyopathyNeuromuscular diseasemedicine.diseasePhenotypeComputer Science Applications030104 developmental biologyFriedreich AtaxiaNext-generation sequencingmedicine.symptomStatistics Probability and Uncertaintybusiness030217 neurology & neurosurgeryInformation SystemsScientific data
researchProduct

Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab

2017

Nivolumab is a programmed death-1 (PD-1)inhibitor recently approved for the treatment of NSCLC patients who failed prior chemotherapy. Searching for predictive biomarkers of immunotherapy efficacy is an area of intensive investigation for translational research. Monitoring circulating tumor DNA (ctDNA) during nivolumab treatment could help clinicians to predict the immunotherapy efficacy and ultimately improve the management of patients

0301 basic medicinebusiness.industrymedicine.medical_treatment02 engineering and technologyHematologyImmunotherapyctDNA biomarker NSCLC Nivolumab immunotherapy021001 nanoscience & nanotechnology03 medical and health sciences030104 developmental biologyOncologyCirculating tumor DNACancer researchMedicineBiomarker (medicine)Nivolumab0210 nano-technologybusinessPredictive biomarker
researchProduct

Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer

2021

Thyroid cancer is the most common malignancy of the endocrine system, encompassing different entities with distinct histological features and clinical behavior. The diagnostic definition, therapeutic approach, and follow-up of thyroid cancers display some controversial aspects that represent unmet medical needs. Liquid biopsy is a non-invasive approach that detects and analyzes biological samples released from the tumor into the bloodstream. With the use of different technologies, tumor cells, free nucleic acids, and extracellular vesicles can be retrieved in the serum of cancer patients and valuable molecular information can be obtained. Recently, a growing body of evidence is accumulating…

0301 basic medicinediagnosisQH301-705.5differentiated thyroid cancerReviewNeoplastic CellsMalignancymedullary thyroid cancerCatalysisInorganic ChemistryExtracellular Vesicles03 medical and health sciences0302 clinical medicineCirculating tumor cellBiomarkers TumorCirculatingmedicineHumansThyroid NeoplasmsBiology (General)Physical and Theoretical ChemistryAnaplastic thyroid cancerLiquid biopsyQD1-999Molecular BiologyThyroid cancerSpectroscopyTumorliquid biopsybusiness.industryOrganic ChemistryThyroidMedullary thyroid cancerCancerGeneral MedicineNeoplastic Cells Circulatingmedicine.diseaseComputer Science ApplicationsChemistry030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisCancer researchTherapyprognosisbusinessCell-Free Nucleic AcidsBiomarkersanaplastic thyroid cancerInternational Journal of Molecular Sciences
researchProduct

Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease—results from the large AtheroGene study

2016

Introduction Stratification for subsequent coronary events among patients with coronary artery disease (CAD) is of considerable interest because of the potential to guide secondary preventive therapies. Recently, we identified eight microRNAs (miRNAs), which facilitated acute coronary syndrome (ACS) diagnosis. In this study, we aimed to evaluate their potential role as prognostic biomarkers for cardiovascular disease. Methods The serum concentrations of eight candidate miRNAs -miR-19a, miR-19b, miR-132, miR-140-3p, miR-142-5p, miR-150, miR-186, and miR-210 were measured in a cohort of 1112 patients with documented CAD—including 430 patients with ACS and 682 patients with stable angina pecto…

0301 basic medicinemedicine.medical_specialtyAcute coronary syndromePathologyProportional hazards modelbusiness.industryDisease030204 cardiovascular system & hematologymedicine.diseaseCoronary artery disease03 medical and health sciencesCirculating MicroRNA030104 developmental biology0302 clinical medicineInternal medicineCohortmedicineCardiologyBiomarker (medicine)Cardiology and Cardiovascular MedicineRisk assessmentbusinessEuropean Heart Journal
researchProduct

2018

Background Attempts to establish a biomarker reflecting individual player load in intermittent sports such as football have failed so far. Increases in circulating DNA (cfDNA) have been demonstrated in various endurance sports settings. While it has been proposed that cfDNA could be a suitable marker for player load in intermittent sports, the effects on cfDNA of repeated sprinting as an essential feature in intermittent sports are unknown. For the first time, we assessed both alterations of cfDNA due to repeated maximal sprints and due to a professional football game. Methods Nine participants were subjected to a standardised sprint training session with cross-over design of five maximal s…

0301 basic medicinemedicine.medical_specialtyFootball playersMultidisciplinarybusiness.industry030229 sport sciencesCirculating Cell-Free DNAIncremental exerciseSprint training03 medical and health sciences030104 developmental biology0302 clinical medicineSprintInternal medicinemedicineCardiologyCirculating DNATracking databusinesshuman activitiesPLOS ONE
researchProduct

Tumor Heterogeneity, Single-Cell Sequencing, and Drug Resistance

2016

Tumor heterogeneity has been compared with Darwinian evolution and survival of the fittest. The evolutionary ecosystem of tumors consisting of heterogeneous tumor cell populations represents a considerable challenge to tumor therapy, since all genetically and phenotypically different subpopulations have to be efficiently killed by therapy. Otherwise, even small surviving subpopulations may cause repopulation and refractory tumors. Single-cell sequencing allows for a better understanding of the genomic principles of tumor heterogeneity and represents the basis for more successful tumor treatments. The isolation and sequencing of single tumor cells still represents a considerable technical ch…

0301 basic medicineprecision medicinelcsh:Medicinelcsh:RS1-441Pharmaceutical ScienceReviewsingle-cell sequencingcirculating tumor cellsBiologylaser-capture microdissectionmulti-region sequencingcancer treatmentDNA sequencinglcsh:Pharmacy and materia medicaxenograft tumor models03 medical and health sciencesCirculating tumor cellDrug DiscoveryIllumina dye sequencingMicrodissectionLaser capture microdissectionnext generation sequencingWhole Genome AmplificationGeneticswhole genome amplificationflow cytometrytumor ecosystemslcsh:RRNA sequencing030104 developmental biologySingle cell sequencingintratumoral heterogeneityindividualized therapyMolecular MedicinePyrosequencingmicromanipulationPharmaceuticals
researchProduct